Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 and VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma with Bone Metastases
NCT02406521Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2015
- Primary completion
- Dec 2017
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of radium-223 dichloride in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Biomarkers of osteoblast and osteoclast activity at 2 Years. Started Apr 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02406521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406521.